CN117945945A - 一种gpr139受体激动剂、其制备方法及其应用 - Google Patents
一种gpr139受体激动剂、其制备方法及其应用 Download PDFInfo
- Publication number
- CN117945945A CN117945945A CN202211338536.5A CN202211338536A CN117945945A CN 117945945 A CN117945945 A CN 117945945A CN 202211338536 A CN202211338536 A CN 202211338536A CN 117945945 A CN117945945 A CN 117945945A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- compound
- pharmaceutically acceptable
- group
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000996780 Homo sapiens Probable G-protein coupled receptor 139 Proteins 0.000 title claims abstract description 36
- 102100033836 Probable G-protein coupled receptor 139 Human genes 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000000018 receptor agonist Substances 0.000 title description 2
- 229940044601 receptor agonist Drugs 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 78
- 150000003839 salts Chemical class 0.000 claims abstract description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 7
- 201000010099 disease Diseases 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 33
- -1 hydroxy, carboxy Chemical group 0.000 claims description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 24
- 229910052736 halogen Inorganic materials 0.000 claims description 17
- 150000002367 halogens Chemical class 0.000 claims description 17
- 125000003545 alkoxy group Chemical group 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- 229920006395 saturated elastomer Polymers 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 125000002252 acyl group Chemical group 0.000 claims description 10
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims description 8
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 8
- 125000005189 alkyl hydroxy group Chemical group 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 6
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 5
- 239000000460 chlorine Substances 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 5
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 5
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 208000007848 Alcoholism Diseases 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 206010003805 Autism Diseases 0.000 claims description 3
- 208000020706 Autistic disease Diseases 0.000 claims description 3
- 206010013654 Drug abuse Diseases 0.000 claims description 3
- 206010026749 Mania Diseases 0.000 claims description 3
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 3
- 206010034010 Parkinsonism Diseases 0.000 claims description 3
- 206010001584 alcohol abuse Diseases 0.000 claims description 3
- 208000025746 alcohol use disease Diseases 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 208000011117 substance-related disease Diseases 0.000 claims description 3
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 2
- 206010010904 Convulsion Diseases 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 230000036461 convulsion Effects 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 125000003003 spiro group Chemical group 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 59
- 238000006243 chemical reaction Methods 0.000 description 50
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 34
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 27
- 238000004458 analytical method Methods 0.000 description 21
- 239000012074 organic phase Substances 0.000 description 21
- 238000004809 thin layer chromatography Methods 0.000 description 21
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- 239000007787 solid Substances 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 16
- 239000002994 raw material Substances 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 13
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 9
- 239000007858 starting material Substances 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
- 239000007995 HEPES buffer Substances 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 6
- 229940054269 sodium pyruvate Drugs 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102100020756 D(2) dopamine receptor Human genes 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- 101000931901 Homo sapiens D(2) dopamine receptor Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 108010019160 Pancreatin Proteins 0.000 description 3
- 101000767160 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Intracellular protein transport protein USO1 Proteins 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000003185 calcium uptake Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229940055695 pancreatin Drugs 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- WEZXQPGVPSHAAZ-RGMNGODLSA-N (1s)-1-(2-fluorophenyl)ethanamine;hydrochloride Chemical compound Cl.C[C@H](N)C1=CC=CC=C1F WEZXQPGVPSHAAZ-RGMNGODLSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 101100348848 Mus musculus Notch4 gene Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 210000004898 n-terminal fragment Anatomy 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229960005190 phenylalanine Drugs 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 238000012746 preparative thin layer chromatography Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- KWVVTSALYXIJSS-UHFFFAOYSA-L silver(ii) fluoride Chemical compound [F-].[F-].[Ag+2] KWVVTSALYXIJSS-UHFFFAOYSA-L 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 2
- PDPHGCQJDUZZGM-YFKPBYRVSA-N (1s)-1-(2,6-difluorophenyl)ethanamine Chemical compound C[C@H](N)C1=C(F)C=CC=C1F PDPHGCQJDUZZGM-YFKPBYRVSA-N 0.000 description 1
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- TXTWXQXDMWILOF-UHFFFAOYSA-N (2-ethoxy-2-oxoethyl)azanium;chloride Chemical compound [Cl-].CCOC(=O)C[NH3+] TXTWXQXDMWILOF-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- MLFIYYDKLNZLAO-UHFFFAOYSA-N 2-aminoethane-1,1-diol Chemical compound NCC(O)O MLFIYYDKLNZLAO-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 101150057121 GPR12 gene Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 108010088565 Melanocortin 5 receptor Proteins 0.000 description 1
- 102100023726 Melanocortin receptor 3 Human genes 0.000 description 1
- 102100023723 Melanocortin receptor 5 Human genes 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100446506 Mus musculus Fgf3 gene Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108010021433 Type 3 Melanocortin Receptor Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001175 calcium sulphate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 150000001945 cysteines Chemical group 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 102000052207 human GPR139 Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 235000013930 proline Nutrition 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- GRJJQCWNZGRKAU-UHFFFAOYSA-N pyridin-1-ium;fluoride Chemical compound F.C1=CC=NC=C1 GRJJQCWNZGRKAU-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- UAEJRRZPRZCUBE-UHFFFAOYSA-N trimethoxyalumane Chemical compound [Al+3].[O-]C.[O-]C.[O-]C UAEJRRZPRZCUBE-UHFFFAOYSA-N 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明提供了一种如式(I)所示的化合物,或其在药学上可接受的盐,其中,R1、R2、R3、R4和R5等具有说明书中给出的定义。此外,本发明还提供了所述化合物及其药学上可接受的盐的制备方法,以及其在制备用于治疗或预防GPR139受体相关疾病的药物中的应用。
Description
技术领域
本发明涉及药物化学领域。具体地,本发明涉及一类G蛋白偶联受体139(GProtein-coupled Receptor 139,简称GPR139)的配体分子。
背景技术
G蛋白偶联受体139(G Protein-coupled Receptor 139,简称GPR139)是Gloriam等于2005年首次发现(Biochim Biophys Acta 2005;1722:235-246),也被称为GPCR12,PGR3,KOR3L,GPRg1。GPR139主要表达在中枢神经系统(CNS)中的缰核、纹状核、丘脑、下丘脑和垂体中,其氨基酸序列在不同物种中具有高度保守性如人GPR139蛋白序列与小鼠、鸡和斑马鱼的同源性分别为96%,92%和70%。GPR139受体表达在细胞表面时,由N-端片段、7个穿膜片段和C-端片段组成,其中N-端片段由26个氨基酸组成,并含有一个半胱氨酸。Wang等报道,GPR139受体和多巴胺受体D2共表达于鼠脑的不同组织中,并通过体外细胞实验证实GPR139能促进多巴胺受体D2的激动剂产生钙流信号,且该钙流信号既能被多巴胺受体D2的拮抗剂,也能被GPR139的拮抗剂所抑制(Frontiers in Neuroscience,March 2019,Volume13,Article 281)。此外,Nepomuceno等证实GPR139能通黑色皮质素受体3或5(MC3/MC5)起协同作用。这些结果表明,GPR139能与细胞表面其它受体形成异源二聚体发挥生理作用。此外,我们的实验已证实GPR139受体能通过N-端的半胱氨酸形成同源二聚体。
不同研究团队在寻找GPR139的配体,包括激动剂和拮抗剂,的同时,Liu等报告了L-苯丙氨酸和L-色氨酸为GPR139内源性激动剂(Mol Pharmacol 2015;88:911-925)。
现有的研究表明,GPR139受体具有重要的生理功能,是抗焦虑、抗抑郁、抗精神分裂,治疗帕金森综合症,治疗药物和酒精滥用,治疗自闭症,治疗癫痫,治疗狂躁症,治疗代谢相关疾病的潜在药物靶点。相关GPR139的结构、表达、药理、生理功能信息为设计和合成全新的GPR139激动剂提供了坚实的基础。
发明内容
在本发明的第一方面,提供了一种如式(I)所示的化合物、其氘代物,或其药学上可接受的盐,
其中,
X选自下组:N、CH;
R1、R2各自独立选自下组:氢、卤素、羟基、羧基、C1-3烷基、C1-6酰基、C1-3烷基-羰基-C1-3烷基、C1-6烷基-羟基、C1-6烷基-醛基、C1-6烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基;
R3选自下组:氢、卤素、羟基、羧基、C1-6酰基、C1-3烷基-羰基-C1-3烷基、C1-6烷基-羟基、C1-6烷基-醛基、C1-6烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C3-8饱和或不饱和碳环基、3-10元饱和或不饱和杂环基、C6-10芳基、5-12元杂芳基;
R4选自下组:氢、卤素、羧基、C1-6酰基、C1-3烷基-羰基-C1-3烷基、C1-6烷基-羟基、C1-6烷基-醛基、C1-6烷基、C1-6卤代烷基;
R5、R6、R7、R8和R9各自独立选自下组:氢、卤素、羟基、羧基、C1-6酰基、C1-3烷基-羰基-C1-3烷基、C1-6烷基-醛基、C1-6烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基;
其中,所述的碳环基、杂环基、芳基、杂芳基可以为单环、螺环、稠环或桥环结构的基团。
在部分实施方式中,R1、R2各自独立选自下组:氢、卤素、羟基、羧基、C1-3烷基、C1-3烷氧基、C1-3卤代烷基、C1-3卤代烷氧基。
在另一优选例中,R1、R2各自独立选自下组:氢、氯、氟、-CH3、-CF3、-OCH3。
在部分实施方式中,R3选自下组:氢、卤素、羟基、羧基、C1-3酰基、C1-3烷基-羰基-C1-3烷基、C1-3烷基-羟基、C1-3烷基-醛基、C1-3烷基、C1-3卤代烷基、C1-3烷氧基。
在另一优选例中,R3选自下组:氢、-CH2OH。
在部分实施方式中,R4选自下组:氢、C1-3烷基、C1-3卤代烷基、C3-6饱和或部分不饱和碳环基、3-10元饱和或部分不饱和杂环基。
在另一优选例中,R4为氢、甲基。
在部分实施方式中,R5、R6、R7、R8和R9各自独立选自下组:氢、卤素、羟基、羧基、C1-3烷基、C1-3烷氧基、C1-3卤代烷基、C1-3卤代烷氧基。
在另一优选例中,R5、R6、R7、R8和R9各自独立选自下组:氢、氟、氯。
在部分实施方式中,所述的化合物选自下组:
在本发明的第二方面,提供了一种如本发明第一方面所述的化合物、或其药学上可接受的盐的制备方法,包括步骤:
或者
其中,X、R1、R2、R3、R4、R5、R6、R7、R8和R9的定义如前所述。
在本发明的第三方面,提供了一种药物组合物,其特征在于,包括(1)如本发明第一方面所述的化合物、其氘代物,或其药学上可接受的盐;和(2)药学上可接受的载体。
在本发明的第四方面,提供了如本发明第三方面所述的药物组合物的制备方法,其特征在于,包括步骤:将本发明第一方面所述的化合物、其氘代物,或其药学上可接受的盐,与药学上可接受的载体进行混合,从而形成药物混合物。
在本发明的第五方面,提供了如本发明第一方面所述的化合物、其氘代物,或其药学上可接受的盐,或者本发明第三方面所述的药物组合物的用途,其特征在于,用于制备用于治疗或预防GPR139受体相关疾病的药物。
在另一优选例中,所述GPR139受体相关疾病包括焦虑症、抑郁症、狂躁症、帕金森综合症、药物及酒精滥用、精神分裂症、自闭症、惊厥、癫痫。
应理解,在本发明范围内中,本发明的上述各技术特征和在下文(如实施例)中具体描述的各技术特征之间都可以互相组合,从而构成新的或优选的技术方案。限于篇幅,在此不再一一累述。
具体实施方式
发明人经过广泛而深入的研究,出乎意料地发现本发明化合物具有优异的GPR139受体激动活性,从而进行了一系列合成和生物活性测试。在此基础上完成了本发明。
本发明下列实施例中未注明具体条件的实验方法,通常按照常规条件,或按照制造厂商所建议的条件。实施例中所用到的各种常用化学试剂,均为市售产品。
除非另有定义,本发明所使用的所有的技术和科学术语与属于本发明的技术领域的技术人员通常理解的含义相同。本发明的说明书中所使用的术语只是为了描述具体的实施例的目的,不用于限制本发明。
术语
本发明的术语“包括”和“具有”以及它们任何变形,意图在于覆盖不排他的包含。例如包含了一系列步骤的过程、方法、装置、产品或设备没有限定于已列出的步骤或模块,而是可选地还包括没有列出的步骤,或可选地还包括对于这些过程、方法、产品或设备固有的其它步骤。
在本发明中提及的“多个”是指两个或两个以上。“和/或”,描述关联对象的关联关系,表示可以存在三种关系,例如,A和/或B,可以表示:单独存在A,同时存在A和B,单独存在B这三种情况。字符“/”一般表示前后关联对象是一种“或”的关系。
本发明所述化合物中,当任何变量在任何组分中出现超过一次,则其每次出现的定义独立于其它每次出现的定义。同样,允许取代基及变量的组合,只要这种组合使化合物稳定。自取代基划入环系统的线表示所指的键可连接到任何能取代的环原子上。如果环系统为多环,其意味着这种键仅连接到邻近环的任何适当的碳原子上。要理解本领域普通技术人员可选择本发明化合物的取代基及取代型式而提供化学上稳定的并可通过本领域技术和下列提出的方法自可容易获得的原料容易合成的化合物。如果取代基自身被超过一个基团取代,应理解这些基团可在相同碳原子上或不同碳原子上,只要使结构稳定。
本文所用术语“烷基”意指包括具有特定碳原子数目的支链的和直链的饱和脂肪烃基。例如,“C1-C8烷基”中“C1-C8”的定义包括以直链或支链排列的具有1、2、3、4、5、、或8个碳原子的基团。术语“环烷基”指具有特定碳原子数目的单环饱和脂肪烃基。例如“环烷基”包括环丙基、甲基-环丙基、2,2-二甲基-环丁基、2-乙基-环戊基、环己基等。
本文所用术语“烷氧基”代表烷基-氧基基团,其中烷基的定义如上所示。
正如本领域技术人员所理解的,本文中所用“卤素”意指包括氯、氟、溴和碘。
本文所用术语“卤代烷基”代表其中有一个或多个氢原子被卤素取代的烷基基团,其中烷基的定义如上所示。
本文所用术语“卤代烷氧基”代表有一个或多个氢原子被卤素取代的烷基-氧基基团,其中烷基的定义如上所示。
活性成分
在本发明中,提供了一种可有效激动GPR139受体的活性成分。该活性成分为通式(I)所示的化合物,该活性成分可有效预防、治疗和/或缓解GPR139相关疾病。
试验表明,本发明的活性成分可有效地激动GPR139受体,从而预防、治疗和/或缓解GPR139相关疾病。
应理解,本发明的活性成分包括通式(I)所示的化合物、或其药学上可接受的盐、或其前药。应理解,本发明的活性成分还包括通式(I)化合物的晶型、无定形化合物、以及氘代化合物等形式。
术语“药学上可接受的盐”指本发明化合物与酸或碱所形成的适合用作药物的盐。药学上可接受的盐包括无机盐和有机盐。一类优选的盐是本发明化合物与酸形成的盐。适合形成盐的酸包括但并不限于:盐酸、氢溴酸、氢氟酸、硫酸、硝酸、磷酸等无机酸;甲酸、乙酸、三氟乙酸、丙酸、草酸、丙二酸、琥珀酸、富马酸、马来酸、乳酸、苹果酸、酒石酸、柠檬酸、苦味酸、苯甲酸、甲磺酸、乙磺酸、对甲苯磺酸、苯磺酸、萘磺酸等有机酸;以及脯氨酸、苯丙氨酸、天冬氨酸、谷氨酸等氨基酸。另一类优选的盐是本发明化合物与碱形成的盐,例如碱金属盐(例如钠盐或钾盐)、碱土金属盐(例如镁盐或钙盐)、铵盐(如低级的烷醇铵盐以及其它药学上可接受的胺盐),例如甲胺盐、乙胺盐、丙胺盐、二甲基胺盐、三甲基胺盐、二乙基胺盐、三乙基胺盐、叔丁基胺盐、乙二胺盐、羟乙胺盐、二羟乙胺盐、三羟乙胺盐,以及分别由吗啉、哌嗪、赖氨酸形成的胺盐。
制备方法
下面更具体地描述本发明式(I)结构化合物的制备方法,但这些具体方法不对本发明构成任何限制。本发明化合物还可以任选将在本说明书中描述的或本领域已知的各种合成方法组合起来而方便地制得,这样的组合可由本发明所属领域的技术人员容易地进行。
通常,在制备流程中,各反应通常在惰性溶剂中,在室温至回流温度(如0℃~80℃,优选0℃~50℃)下进行。反应时间通常为0.1小时-60小时,较佳地为0.5-48小时。
下面的通用制备路线可以用于合成本发明式(I)结构的化合物。
或者
药物组合物和施用方法
由于本发明化合物具有优异的GPR139受体激动活性,因此本发明化合物及其各种晶型,药学上可接受的无机或有机盐,水合物或溶剂合物,以及含有本发明化合物为主要活性成分的药物组合物可用于治疗、预防以及缓解与GPR139受体相关的疾病。
本发明的药物组合物包含安全有效量范围内的本发明化合物或其药理上可接受的盐及药理上可以接受的赋形剂或载体。其中“安全有效量”指的是:化合物的量足以明显改善病情,而不至于产生严重的副作用。通常,药物组合物含有1-3000(活性剂量范围3-30mg/kg)mg本发明化合物/剂,更佳地,含有10-2000mg本发明化合物/剂。较佳地,所述的“一剂”为一个胶囊或药片。
“药学上可以接受的载体”指的是:一种或多种相容性固体或液体填料或凝胶物质,它们适合于人使用,而且必须有足够的纯度和足够低的毒性。“相容性”在此指的是组合物中各组份能和本发明的化合物以及它们之间相互掺和,而不明显降低化合物的药效。药学上可以接受的载体部分例子有纤维素及其衍生物(如羧甲基纤维素钠、乙基纤维素钠、纤维素乙酸酯等)、明胶、滑石、固体润滑剂(如硬脂酸、硬脂酸镁)、硫酸钙、植物油(如豆油、芝麻油、花生油、橄榄油等)、多元醇(如丙二醇、甘油、甘露醇、山梨醇等)、乳化剂润湿剂(如十二烷基硫酸钠)、着色剂、调味剂、稳定剂、抗氧化剂、防腐剂、无热原水等。
本发明化合物或药物组合物的施用方式没有特别限制,代表性的施用方式包括(但并不限于):口服、瘤内、直肠、肠胃外(静脉内、肌肉内或皮下)、和局部给药。
用于口服给药的固体剂型包括胶囊剂、片剂、丸剂、散剂和颗粒剂。在这些固体剂型中,活性化合物与至少一种常规惰性赋形剂(或载体)混合,如柠檬酸钠或磷酸二钙,或与下述成分混合:(a)填料或增容剂,例如,淀粉、乳糖、蔗糖、葡萄糖、甘露醇和硅酸;(b)粘合剂,例如,羟甲基纤维素、藻酸盐、明胶、聚乙烯基吡咯烷酮、蔗糖和阿拉伯胶;(c)保湿剂,例如,甘油;(d)崩解剂,例如,琼脂、碳酸钙、马铃薯淀粉或木薯淀粉、藻酸、某些复合硅酸盐、和碳酸钠;(e)缓溶剂,例如石蜡;(f)吸收加速剂,例如,季胺化合物;(g)润湿剂,例如鲸蜡醇和单硬脂酸甘油酯;(h)吸附剂,例如,高岭土;和(i)润滑剂,例如,滑石、硬脂酸钙、硬脂酸镁、固体聚乙二醇、十二烷基硫酸钠,或其混合物。胶囊剂、片剂和丸剂中,剂型也可包含缓冲剂。
固体剂型如片剂、糖丸、胶囊剂、丸剂和颗粒剂可采用包衣和壳材制备,如肠衣和其它本领域公知的材料。它们可包含不透明剂,并且,这种组合物中活性化合物或化合物的释放可以延迟的方式在消化道内的某一部分中释放。可采用的包埋组分的实例是聚合物质和蜡类物质。必要时,活性化合物也可与上述赋形剂中的一种或多种形成微胶囊形式。
用于口服给药的液体剂型包括药学上可接受的乳液、溶液、悬浮液、糖浆或酊剂。除了活性化合物外,液体剂型可包含本领域中常规采用的惰性稀释剂,如水或其它溶剂,增溶剂和乳化剂,例知,乙醇、异丙醇、碳酸乙酯、乙酸乙酯、丙二醇、1,3-丁二醇、二甲基甲酰胺以及油,特别是棉籽油、花生油、玉米胚油、橄榄油、蓖麻油和芝麻油或这些物质的混合物等。
除了这些惰性稀释剂外,组合物也可包含助剂,如润湿剂、乳化剂和悬浮剂、甜味剂、矫味剂和香料。
除了活性化合物外,悬浮液可包含悬浮剂,例如,乙氧基化异十八烷醇、聚氧乙烯山梨醇和脱水山梨醇酯、微晶纤维素、甲醇铝和琼脂或这些物质的混合物等。
用于肠胃外注射的组合物可包含生理上可接受的无菌含水或无水溶液、分散液、悬浮液或乳液,和用于重新溶解成无菌的可注射溶液或分散液的无菌粉末。适宜的含水和非水载体、稀释剂、溶剂或赋形剂包括水、乙醇、多元醇及其适宜的混合物。
用于局部给药的本发明化合物的剂型包括软膏剂、散剂、贴剂、喷射剂和吸入剂。活性成分在无菌条件下与生理上可接受的载体及任何防腐剂、缓冲剂,或必要时可能需要的推进剂一起混合。
本发明化合物可以单独给药,或者与其他药学上可接受的化合物联合给药。
使用药物组合物时,是将安全有效量的本发明化合物适用于需要治疗的哺乳动物(如人),其中施用时剂量为药学上认为的有效给药剂量,对于60kg体重的人而言,日给药剂量通常为1~2000mg,优选6~600mg。当然,具体剂量还应考虑给药途径、病人健康状况等因素,这些都是熟练医师技能范围之内的。
本发明的主要优点包括:
(a)本发明化合物可高效地激动GPR139受体,部分化合物的EC50值<0.1μM。
(b)本发明化合物合成简单,产率较高。
(c)本发明化合物的毒副作用低,成药性好。
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法,通常按照常规条件,或按照制造厂商所建议的条件。除非另外说明,否则百分比和份数按重量计算。本发明中用到的起始原料未经特别说明,均为商业购买。
实施例
实施例1化合物NRB153的制备
第一步:
将原料1(1.5克,10.75毫摩尔)和原料A(1克,7.16毫摩尔),EDCl(2.75克,14.33毫摩尔),HOBt(1.93克,14.33毫摩尔),二异丙基乙胺(1.85克,14.33毫摩尔)用50毫升二氯甲烷溶解,室温搅拌过夜。通过TLC来监测反应完成。加入水溶液(50毫升),二氯甲烷萃取(3x50毫升),有机相用无水硫酸钠干燥,浓缩干后通过柱层析来分离纯化,得到产品1.6克的无色油状物。分析数据:LCMS(ESI+):m/z 226(M+H)。
第二步:
将中间体2(1.6克,7.11毫摩尔)用四氢呋喃(20毫升)和水(20毫升)溶解,加入LiOH.H2O(896毫克,21.33毫摩尔)。反应在室温条件下搅拌两小时。通过TLC来监测反应完成。反应结束后用1摩尔/升的稀盐酸溶液调节pH至3到4.乙酸乙酯萃取(3x30毫升),有机相用无水硫酸钠干燥,浓缩干后得到产品1.3克的白色固体产物。分析数据:LCMS(ESI+):m/z198(M+H)。
第三步:
将中间体Int-1(84毫克,0.43毫摩尔)和(S)-1-(2-氟苯基)乙胺盐酸盐(50毫克,0.28毫摩尔),EDCl(109毫克,0.57毫摩尔),HOBt(77毫克,0.57毫摩尔),二异丙基乙胺(74毫克,0.571毫摩尔)用3毫升二氯甲烷溶解,室温搅拌四小时。通过TLC来监测反应完成。加入水溶液(5毫升)淬灭反应,二氯甲烷萃取(3x3毫升),有机相用无水硫酸钠干燥,浓缩干后通过制备薄层色谱法来分离纯化,得到产品50毫克的白色固体。分析数据:LCMS(ESI+):m/z319(M+H);1HNMR(300MHz,CDCl3)δ7.57-7.52(m,2H),7.45-7.37(m,1H),7.30-7.28(m,1H),7.26-7.19(m,2H),7.13-6.96(m,3H),6.60-6.53(m,1H),5.31(q,J=7.2Hz,1H),4.18-4.12(m,2H),1.54(d,J=7.2Hz,3H).
实施例2-5
采用实施例1的方法,不同点在于:采用不同底物替换Int-1和/或(S)-1-(2-氟苯基)乙胺盐酸盐,从而制得化合物2-5。
实施例6化合物NRB156的制备
第一步:
将原料1(1.5克,5.69毫摩尔)和原料A(1.2克,6.86毫摩尔),EDCl(2.18克,11.39毫摩尔),HOBt(1.54克,11.39毫摩尔),二异丙基乙胺(1.47克,11.393毫摩尔)用20毫升二氯甲烷溶解,室温搅拌2小时。通过TLC来监测反应完成。加入饱和氯化钠水溶液(20毫升),二氯甲烷萃取(3x10毫升),有机相用无水硫酸钠干燥,浓缩干后通过柱层析来分离纯化,得到产品1.08克的无色油状物。分析数据:LCMS(ESI+):m/z 297(M+H)。
第二步:
将中间体2(1.08克,3.68毫摩尔)用甲醇(5毫升)溶解,加入HCl的乙醚溶液(5mL,浓度约4摩尔/升)。反应在室温条件下搅拌1.5小时。通过TLC来监测反应完成。反应结束后真空浓缩得到产品746毫克。分析数据:LCMS(ESI+):m/z 197(M+H)。
第三步:
将中间体Int-2(40毫克,0.17毫摩尔)和原料B(29毫克,0.206毫摩尔),EDCl(66毫克,0.344毫摩尔),HOBt(46毫克,0.344毫摩尔),二异丙基乙胺(66毫克,0.516毫摩尔)用1毫升二氯甲烷溶解,室温搅拌1小时。通过TLC来监测反应完成。加入饱和NaCl水溶液(5毫升)淬灭反应,二氯甲烷/甲醇萃取(10/1,3x5毫升),有机相用无水硫酸钠干燥,浓缩干后通过制备薄层色谱法来分离纯化,得到产品39毫克的白色固体。分析数据:LCMS(ESI+):m/z320(M+H);1HNMR(300MHz,DMSO-d6)δ8.94-8.86(m,1H),8.74-8.68(m,1H),8.53(d,J=7.8Hz,1H),7.82(dd,J=9.6,2.1Hz,1H),7.60-7.54(m,1H),7.47-7.36(m,1H),7.34-7.24(m,1H),7.22-7.01(m,2H),5.18(q,J=7.2Hz,1H),4.04-3.98(m,2H),1.36(d,J=7.2Hz,3H).
实施例7化合物NRB162-b的制备
第一步:
将原料1(300毫克,2.14毫摩尔)和原料A(365毫克,2.36毫摩尔),HATU(1.22克,3.21毫摩尔),Et3N(432毫克,4.29毫摩尔),用20毫升二氯甲烷溶解,室温搅拌2小时。通过TLC来监测反应完成。加入饱和氯化钠水溶液(20毫升),二氯甲烷萃取(3x10毫升),有机相用无水硫酸钠干燥,浓缩干后通过柱层析来分离纯化,得到产品335毫克的无色油状物。分析数据:LCMS(ESI+):m/z 242(M+H)。
第二步:
将中间体2(335毫克,1.37毫摩尔)用甲醇(15毫升)溶解,加入LiOH.H2O(66毫克,2.74毫摩尔)溶于5毫升水的溶液。室温搅拌2小时。通过TLC来监测反应完成。反应结束真空浓缩掉甲醇,水相再用乙酸乙酯萃取除去杂质,然后水相用1MHCl调节pH到2.再用DCM/MeOH=10:1(3x30mL)萃取,合并有机相,干燥后真空浓缩得到产品175毫克黄色油状物。分析数据:LCMS(ESI+):m/z 228(M+H)。
第三步:
将原料3(100毫克,0.44毫摩尔)和原料B(93毫克,0.53毫摩尔),HATU(251毫克,0.66毫摩尔),Et3N(89毫克,0.88毫摩尔),用10毫升二氯甲烷溶解,室温搅拌2小时。通过TLC来监测反应完成。加入饱和氯化钠水溶液(20毫升),二氯甲烷萃取(3x10毫升),有机相用无水硫酸钠干燥,浓缩干后通过柱层析来分离纯化,得到产品57毫克的无色油状物。通过进一步分离得到17.8毫克162-a(peak 1),17.7毫克162-b(peak 2)。分析数据:162-a:LCMS(ESI+):m/z 349(M+H);1HNMR(300MHz,CD3OD)7.74-7.65(m,1H),7.62-7.60(m,1H),7.54-7.47(m,1H),7.42-7.36(m,1H),7.33-7.22(m,2H),7.16-7.06(m,2H),5.31-5.24(m,1H),4.70-4.60(m,1H),3.87-3.85(m,2H),1.48(d,J=6.9Hz,3H).
162-b:LCMS(ESI+):m/z 349(M+H);1HNMR(300MHz,CD3OD)7.67-7.61(m,1H),7.59-7.52(m,1H),7.49-7.45(m,1H),7.43-7.38(m,1H),7.32-7.21(m,2H),7.14-7.00(m,2H),5.30-5.25(m,1H),4.70-4.67(m,1H),3.91-3.88(m,2H),1.47(d,J=6.9Hz,3H).
实施例8化合物NRB181的制备
第一步:
将S1(2克,12.7毫摩尔)和甘氨酸乙酯盐酸盐(1.75克,14.0毫摩尔),EDCl(3.16克,16.5毫摩尔),HOBt(2.51克,16.5毫摩尔),二异丙基乙胺(4.9克,38.1毫摩尔)用60毫升二氯甲烷溶解,室温搅拌过夜。通过TLC来监测反应完成。加入水溶液(100毫升)淬灭反应,二氯甲烷萃取(3x80毫升),有机相用无水硫酸钠干燥,浓缩干后通过柱层析来分离纯化,得到产品478毫克的类白色固体。分析数据:LCMS(ESI+):m/z 229(M+H)。
第二步:
将中间体2(478毫克,2.1毫摩尔)用四氢呋喃(6毫升)和水(3毫升)溶解,加入氢氧化锂(352毫克,8.4毫摩尔)。反应在室温条件下搅拌2小时。通过TLC来监测反应完成。反应结束后将反应浓缩,除去大部分四氢呋喃,剩余反应液加水50毫升,用乙酸乙酯萃取一遍,除去杂质。将剩余水相调至PH约为4,再用乙酸乙酯萃取3次(3x30毫升),有机相用无水硫酸钠干燥后浓缩,得到325毫克白色固体Int-3。分析数据:LCMS(ESI+):m/z 215(M+H)。
第三步:
将中间体Int-3(30毫克,0.14毫摩尔)和(S)-1-(2,6-二氟苯基)乙胺
(33毫克,0.17毫摩尔),HATU(106毫克,0.28毫摩尔),二异丙基乙胺(54毫克,0.42毫摩尔),用1毫升二氯甲烷溶解,室温搅拌3小时。通过TLC来监测反应完成。加入氯化铵水溶液(5毫升)淬灭反应,二氯甲烷萃取(3x5毫升),有机相用无水硫酸钠干燥,浓缩干后通过薄层制备板分离,得到产品29毫克的白色固体。分析数据:LCMS(ESI+):m/z 354(M+H);1HNMR(300MHz,CD3OD)δ8.57(d,J=5.1Hz,1H),8.08(s,1H),7.62(d,J=3.3Hz,1H),7.32-7.22(m,1H),6.92(t,J=8.1Hz,2H),5.49-5.41(m,1H),4.11-4.06(m,2H),1.53(d,J=7.2Hz,3H).
实施例9化合物NRB211的制备
第一步:
将1(0.5克,3.0毫摩尔)溶于无水乙腈(10毫升)中,氮气保护下将二氟化银(1.3克,8.9毫摩尔)加入反应中,室温反应过夜。通过TLC来监测反应仍有少量原料剩余,加入饱和碳酸氢钠溶液(30毫升)调PH=10,乙酸乙酯(2x30毫升)萃取,有机层用水(2x20毫升)洗,再用饱和氯化钠水溶液(20毫升)洗,有机相用无水硫酸钠干燥,过滤浓缩干后通过柱层析来分离纯化,得到产品160毫克的黄色固体。分析数据:LCMS(ESI+):m/z 186(M+H)。
第二步:
将2(160毫克,0.86毫摩尔)溶于无甲醇(10毫升)中,再加入15%氢氧化钠溶液(3毫升。室温搅拌30分钟,通过TLC来监测反应完全。浓缩反应液至大部分甲醇蒸出,用2N盐酸溶液调PH=3,乙酸乙酯(2x5毫升)萃取,用无水硫酸钠干燥,过滤浓缩得到140毫克固体。分析数据:LCMS(ESI-):m/z 170(M-H)。
第三步:
将原料3(28.6毫克,0.168毫摩尔),HOBt(41毫克,0.30毫摩尔),EDCl(47.2毫克,0.30毫摩尔),用2毫升N,N-二甲基甲酰胺溶解搅拌10分钟后加入原料4(30毫克,0.15毫摩尔),室温搅拌1小时。通过TLC来监测反应完成。加入水溶液(20毫升)淬灭反应,乙酸乙酯萃取(3x10毫升),有机相用无水硫酸钠干燥,浓缩干后通制备板来分离纯化,得到产品30毫克。LCMS(ESI+):m/z 350(M+H).1H NMR(300MHz,CD3OD)δ7.55(s,1H),7.37(t,J=7.2Hz,1H),7.28-7.22(m,1H),7.18-7.11(m,1H),7.10-7.00(m,1H),6.77(d,J=1.5Hz,1H),5.27(q,J=6.9Hz,1H),4.14(s,2H),3.95(s,3H),1.46(d,J=6.9Hz,3H).
实施例10-12
采用实施例16的方法,不同点在于:采用不同底物替换中间体3,从而制得化合物17-20。
实施例13化合物NRB222的制备
第一步:
将原料1(2.0克,10.47毫摩尔)和30%的双氧水(1.78克,15.70毫摩尔)溶于三氟乙酸(8毫升)中,在80-90℃下反应8小时。通过TLC来监测反应少量原料剩余,直接旋干溶剂,得到2.0克的黄色固体。分析数据:LCMS(ESI+):m/z 208(M+H)。
第二步:
将原料2(2.3克,11.11毫摩尔)溶于氯化氢/甲醇(40毫升)中,室温搅拌过夜,通过TLC来监测反应完全。浓缩反应液至大部分甲醇蒸出,用饱和碳酸钠溶液调PH=7-8,用甲基叔丁基醚(2x50毫升)萃取,有机相用饱和氯化钠(50毫升)洗,用无水硫酸钠干燥,过滤浓缩得到2.0克粗品。分析数据:LCMS(ESI-):m/z 222(M+H)。
第三步:
将原料3(2.0克,9.05毫摩尔)溶于三氯氧磷(10毫升),于110℃搅拌4小时。通过TLC来监测反应完成。用饱和碳酸钠溶液调PH=7-8,乙酸乙酯萃取(2x100毫升),有机相用饱和氯化钠(100毫升)洗,用无水硫酸钠干燥,浓缩干后通过柱层析来分离纯化,得到800毫克黄色固体。LCMS(ESI+):m/z 240(M+H).
第四步:
将原料4(100毫克,0.42毫摩尔)溶于无水甲醇(4毫升)中,再加入氢氧化钠(35毫克,0.84毫摩尔)和水(2毫升),室温搅拌30分钟。通过TLC来监测反应完全。浓缩反应液至大部分甲醇蒸出,用2N盐酸溶液调PH=3,用二氯甲烷/甲醇=10/1(2x10毫升)萃取,取有机相用无水硫酸钠干燥,过滤浓缩得到100毫克黄色固体。分析数据:LCMS(ESI-):m/z 224(M-H)。
第五步:
将原料5(23毫克,0.103毫摩尔),HOBt(26毫克,0.186毫摩尔),EDCl(47.2毫克,0.186毫摩尔),用2毫升N,N-二甲基甲酰胺溶解搅拌10分钟后加入原料6(20毫克,0.093毫摩尔),室温搅拌2小时。通过TLC来监测反应完成。加入冰水(50毫升)淬灭反应,乙酸乙酯萃取(2x25毫升),有机相用水(50毫升)洗,用饱和氯化钠(50毫升)洗,取有机相用无水硫酸钠干燥,浓缩干后通制备板来分离纯化,得到15毫克白色固体。LCMS(ESI+):m/z 422(M+H);1HNMR(300MHz,CD3OD)δ8.33(s,1H),8.12(s,1H),7.32-7.23(m,1H),6.92(t,J=8.4Hz,2H),5.44(q,J=7.2Hz,1H),4.10(q,J=16.5Hz,2H),1.53(d,J=7.2Hz,3H).
实施例14-15
采用实施例13的方法,不同点在于:采用不同底物替换中间体3,从而制得化合物17-20。
实施例16
化合物NRB214的制备
第一步:
将S1(1克)用10毫升HBr的乙酸溶液溶解,加热至110℃搅拌过夜。HPLC监测原料还剩40%,将反应液浓缩后再用10毫升HBr的乙酸溶液溶解,加热至110℃搅拌过夜。HPLC监测原料还剩~13%。将反应液浓缩,加入NaHCO3水溶液(20毫升)淬灭反应,乙酸乙酯萃取(2x20毫升),有机相用无水硫酸钠干燥,浓缩干后得到1.5克的黄色固体粗品。分析数据:LCMS(ESI+):m/z 241,243(M+H)。
第二步:
将中间体2(1.5克,6.2毫摩尔)用乙醇(20毫升)溶解,加入醋酸钯(140毫克,0.62毫摩尔),X-Phos(593毫克,1.2毫摩尔),二异丙基乙胺(803毫克,6.2毫摩尔)。在CO体系中,加热至80℃搅拌过夜。HPLC监测原料还剩70%。将反应液抽滤后,重新加入醋酸钯(140毫克,0.62毫摩尔),X-Phos(593毫克,1.2毫摩尔),二异丙基乙胺(803毫克,6.2毫摩尔)。在CO体系中,加热至80℃搅拌过夜。HPLC监测原料还剩~15%。将反应液抽滤浓缩干后通过柱层析来分离纯化,得到产品630毫克的黄色油状物。分析数据:LCMS(ESI+):m/z 235(M+H)。
第三步:
将中间体3(630毫克,2.7毫摩尔)和LiOH.H2O(230毫克,5.4毫摩尔)用10毫升甲醇和5毫升水溶解,室温搅拌1小时。通过LCMS来监测反应完成。反应液直接浓缩,加入5毫升水,乙酸乙酯洗(2x5毫升),水相用1摩尔的稀盐酸调pH=5-6,然后直接浓缩,得到产品500毫克的黄色固体粗品。分析数据:LCMS(ESI+):m/z 207(M+H)。
第四步:
将中间体4(330毫克,1.6毫摩尔)和Int-1(274毫克,1.3毫摩尔),EDCl(615毫克,3.2毫摩尔),HOBt(432.5毫克,3.2毫摩尔),二异丙基乙胺(413.3毫克,3.2毫摩尔)用10毫升二氯甲烷溶解,室温搅拌6小时。通过TLC来监测反应完成。加入氯化铵水溶液(10毫升)淬灭反应,二氯甲烷萃取(2x10毫升),有机相用无水硫酸钠干燥,浓缩干后通过柱层析来分离纯化,得到产品120毫克的白色固体。分析数据:LCMS(ESI+):m/z 403(M+H)。
第五步:
将中间体5(50毫克,0.12毫摩尔)用1毫升氟化氢吡啶溶解,先在四氟瓶中0℃搅拌10分钟。滴加0.5毫升亚硝酸(12.8毫克,0.19毫摩尔)的水溶液。在四氟瓶中0℃搅拌过夜。通过LCMS来监测反应完成。加入三乙胺(2毫升)淬灭反应,乙酸乙酯萃取(2x2毫升),有机相用无水硫酸钠干燥,浓缩干后通过刮大板来分离纯化,得到产品7.6毫克的白色固体。分析数据:LCMS(ESI+):m/z 406(M+H);1H-NMR(300MHz,CDCl3)δ8.40-8.34(m,1H),8.10(d,J=8.4Hz,1H),7.56(dd,J=7.2,2.1Hz,1H),7.21-7.15(m,1H),6.90-6.84(m,2H),6.57-6.53(m,1H),5.64(q,J=7.5Hz,1H),4.21-4.07(m,2H),1.53(d,J=7.5Hz,3H).
实施例17本发明化合物的GPR139受体活性测定
1、实验方法
HEK293细胞生长在含DMEM完全培养基(含有谷氨酰胺、丙酮酸钠、青霉素/链霉素、10%胎牛血清)的10cm培养皿中,于37℃,5% CO2培养箱中培养至90%汇合度。然后传代,每周1:5传代两次。细胞传代时,首先完全吸去培养基,用4mL的DPBS洗一次,加3mL的胰酶消化液,轻摇匀。至细胞裂开时,吸去胰酶消化液,加5mL的DMEM完全培养基。用吸管吹打分散细胞后各加入1mL的分散细胞液至5个新的10cm培养皿中,然后各补加7mL的DMEM完全培养基,混匀后放置37℃,5% CO2培养箱中培养。
在转染细胞的当天,按照适当的密度消化细胞到一个10cm培养皿中,加入6mL的DMEM/F12培养基(含有谷氨酰胺、丙酮酸钠、HEPES、胎牛血清),于37℃,5% CO2培养箱中培养5小时。取一个50mL的无菌离心管A,加1mL无血清DMEM/F12培养基(含有谷氨酰胺、丙酮酸钠、HEPES),再加10μg的GPR139 DNA,混合均匀。取另一个50mL的无菌离心管B,加1mL无血清DMEM培养基(含有谷氨酰胺、丙酮酸钠、HEPES),再加60μL的Fugene HD转染试剂,混合均匀。从离心管B中取1mL的Fugene HD转染试剂,加入到离心管A中,混合均匀,并于室温放置20分钟。加2mL DMEM/F12培养基(含有谷氨酰胺、丙酮酸钠、HEPES、胎牛血清)至离心管A中,混合均匀,然后取出离心管A中的混合物(4ml),加到上述10cm培养皿的细胞中(共10mL液体),混匀后置37℃,5% CO2培养箱中培养20-24小时。
第二天,用胰酶消化液消化转染后的细胞,加适当的DMEM/F12培养基(含有谷氨酰胺、丙酮酸钠、HEPES、青霉素/链霉素、胎牛血清),将细胞接种于Matrigel包被的384-孔板中,细胞密度为6.67×106cells/mL,30μL/孔。将384-孔板置37℃,5% CO2培养箱中培养。
第三天,加10μL/孔FLIPR染料(稀释于含有Pluronic和Probenicid的HEPES溶液中)至384-孔细胞板中,于37℃,5% CO2培养箱中培养40分钟。加入稀释后的化合物到细胞板中,在FLIPR读板仪中读取钙流信号。
用XL-fit软件进行数据分析,并得到每个化合物的EC50值。
2、实验结果
表1、GPR139 FLIPR细胞钙流信号检测化合物的EC50值
在本发明提及的所有文献都在本申请中引用作为参考,就如同每一篇文献被单独引用作为参考那样。此外应理解,在阅读了本发明的上述讲授内容之后,本领域技术人员可以对本发明作各种改动或修改,这些等价形式同样落于本申请所附权利要求书所限定的范围。
Claims (10)
1.一种如式(I)所示的化合物、其氘代物,或其药学上可接受的盐,
其中,
X选自下组:N、CH;
R1、R2各自独立选自下组:氢、卤素、羟基、羧基、C1-3烷基、C1-6酰基、C1-3烷基-羰基-C1-3烷基、C1-6烷基-羟基、C1-6烷基-醛基、C1-6烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基;
R3选自下组:氢、卤素、羟基、羧基、C1-6酰基、C1-3烷基-羰基-C1-3烷基、C1-6烷基-羟基、C1-6烷基-醛基、C1-6烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C3-8饱和或不饱和碳环基、3-10元饱和或不饱和杂环基、C6-10芳基、5-12元杂芳基;
R4选自下组:氢、卤素、羧基、C1-6酰基、C1-3烷基-羰基-C1-3烷基、C1-6烷基-羟基、C1-6烷基-醛基、C1-6烷基、C1-6卤代烷基;
R5、R6、R7、R8和R9各自独立选自下组:氢、卤素、羟基、羧基、C1-6酰基、C1-3烷基-羰基-C1-3烷基、C1-6烷基-醛基、C1-6烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基;
其中,所述的碳环基、杂环基、芳基、杂芳基可以为单环、螺环、稠环或桥环结构的基团。
2.如权利要求1所述的化合物、其氘代物,或其药学上可接受的盐,其特征在于,R1、R2各自独立选自下组:氢、卤素、羟基、羧基、C1-3烷基、C1-3烷氧基、C1-3卤代烷基、C1-3卤代烷氧基。
在另一优选例中,R1、R2各自独立选自下组:氢、氯、氟、-CH3、-CF3、-OCH3。
3.如权利要求1所述的化合物、其氘代物,或其药学上可接受的盐,其特征在于,R3选自下组:氢、卤素、羟基、羧基、C1-3酰基、C1-3烷基-羰基-C1-3烷基、C1-3烷基-羟基、C1-3烷基-醛基、C1-3烷基、C1-3卤代烷基、C1-3烷氧基。
在另一优选例中,R3选自下组:氢、-CH2OH。
4.如权利要求1所述的化合物、其氘代物,或其药学上可接受的盐,其特征在于,R4选自下组:氢、C1-3烷基、C1-3卤代烷基、C3-6饱和或部分不饱和碳环基、3-10元饱和或部分不饱和杂环基。
在另一优选例中,R4为氢、甲基。
5.如权利要求1所述的化合物、其氘代物,或其药学上可接受的盐,其特征在于,R5、R6、R7、R8和R9各自独立选自下组:氢、卤素、羟基、羧基、C1-3烷基、C1-3烷氧基、C1-3卤代烷基、C1-3卤代烷氧基。
在另一优选例中,R5、R6、R7、R8和R9各自独立选自下组:氢、氟、氯。
6.如权利要求1所述的化合物、其氘代物,或其药学上可接受的盐,其特征在于,所述的化合物选自下组:
7.如权利要求1-6任一项所述的化合物、或其药学上可接受的盐的制备方法,包括步骤:
或者
其中,X、R1、R2、R3、R4、R5、R6、R7、R8和R9的定义如权利要求1中所述。
8.一种药物组合物,其特征在于,包括(1)如权利要求1-6任一项所述的化合物、其氘代物,或其药学上可接受的盐;和(2)药学上可接受的载体。
9.如权利要求8所述的药物组合物的制备方法,其特征在于,包括步骤:将权利要求1-6任一项所述的化合物、其氘代物,或其药学上可接受的盐,与药学上可接受的载体进行混合,从而形成药物混合物。
10.如权利要求1-6任一项所述的化合物、其氘代物,或其药学上可接受的盐,或者如权利要求8所述的药物组合物的用途,其特征在于,用于制备用于治疗或预防GPR139受体相关疾病的药物。
在另一优选例中,所述GPR139受体相关疾病包括焦虑症、抑郁症、狂躁症、帕金森综合症、药物及酒精滥用、精神分裂症、自闭症、惊厥、癫痫。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211338536.5A CN117945945A (zh) | 2022-10-28 | 2022-10-28 | 一种gpr139受体激动剂、其制备方法及其应用 |
PCT/CN2023/111008 WO2024087782A1 (zh) | 2022-10-28 | 2023-08-03 | 一种gpr139受体激动剂、其制备方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211338536.5A CN117945945A (zh) | 2022-10-28 | 2022-10-28 | 一种gpr139受体激动剂、其制备方法及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117945945A true CN117945945A (zh) | 2024-04-30 |
Family
ID=90800127
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211338536.5A Pending CN117945945A (zh) | 2022-10-28 | 2022-10-28 | 一种gpr139受体激动剂、其制备方法及其应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN117945945A (zh) |
WO (1) | WO2024087782A1 (zh) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0662529B2 (ja) * | 1984-07-13 | 1994-08-17 | 三共株式会社 | アミノ酸誘導体 |
-
2022
- 2022-10-28 CN CN202211338536.5A patent/CN117945945A/zh active Pending
-
2023
- 2023-08-03 WO PCT/CN2023/111008 patent/WO2024087782A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2024087782A1 (zh) | 2024-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3989972B1 (en) | Glucagon-like peptide 1 receptor agonists | |
KR102622161B1 (ko) | 티에노피리미딘디온 acc 억제제의 고체 형태 및 그의 제조 방법 | |
EP1673078B1 (en) | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease | |
CN113784963B (zh) | 用作ret激酶抑制剂的化合物及其应用 | |
WO2014084298A1 (ja) | リシン構造を有するlsd1選択的阻害薬 | |
CA2693552A1 (en) | Pyridone compound | |
WO2015124063A1 (zh) | 丙肝病毒抑制剂及其制药用途 | |
EP3983384B1 (en) | N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis | |
EP2963027A1 (en) | Tricyclic compound and use thereof | |
TW202003466A (zh) | 人類整合素α4β7拮抗劑 | |
JP2020530490A (ja) | アンドロゲン受容体拮抗薬として使用されるジアリールチオヒダントイン化合物 | |
TW202227397A (zh) | 雙環的-雜環衍生物及相關用途 | |
TW202227433A (zh) | 中環或大環之經苄基取代的雜環衍生物及相關用途 | |
JP2021501184A (ja) | P2x3及び/又はp2x2/3受容体アンタゴニスト、それを含む医薬組成物及びその使用 | |
CN110092779B (zh) | 一种取代的苯基化合物及其应用 | |
JPH01265100A (ja) | 2―置換アデノシン誘導体 | |
RU2162470C2 (ru) | 2,7-замещенные производные октагидропирроло[1,2-а]пиразина, способ лечения, фармацевтическая композиция, промежуточные соединения | |
WO2021129841A1 (zh) | 用作ret激酶抑制剂的化合物及其应用 | |
CN111635373B (zh) | 多环磺酰胺类RORγ调节剂 | |
CA3121952A1 (en) | Macrocyclic compound and use thereof | |
FR2758329A1 (fr) | Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique | |
CN117945945A (zh) | 一种gpr139受体激动剂、其制备方法及其应用 | |
WO2022173795A1 (en) | OXADIAZOLYL DIHYDROPYRANO[2,3-b]PYRIDINE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | |
TWI794576B (zh) | 一類含氟取代的苯并噻吩類化合物及其藥物組合物及應用 | |
WO2021228216A1 (zh) | 可用作RORγ调节剂的联芳基类化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication |